Highest-materiality recent filing
Initiated potential sale or strategic partnership for BE-Smart, a CLIA/CAP-accredited LDT for esophageal cancer risk; outreach to >70 acquirers.
ProPhase Labs secures $10M equity line facility with Generating Alpha Ltd
Stock Purchase Agreement with Generating Alpha Ltd provides up to $10M equity capital at Company's election.
Over $3.3 million of convertible debt converted from $3.8 million principal, reducing indebtedness and increasing equity; remaining unconverted principal less than $500,000.
Nasdaq staff determination on Dec 29, 2025: company failed to regain compliance with minimum $1.00 bid price rule after two 180-day periods ending Dec 22.
ProPhase Labs signs non-binding LOI for reverse merger with ABL, ABL to become majority owner
ProPhase Labs (PRPH) entered a non-binding LOI for a reverse merger with Advanced Biological Laboratories S.A. (ABL), a European biotech firm.
ProPhase Labs to effect 1-for-10 reverse stock split to maintain Nasdaq listing
Stockholders approved reverse stock split on Nov 24, 2025; board approved Nov 30, 2025.
Judgment entered on Nov 5, 2025 in Utah for Avtech equipment lease; company received it on Nov 19, 2025.
ProPhase Q3 net loss $6.8M, revenue down 36%; working capital deficit $47.5M
Q3 net loss from continuing ops $6.8M ($0.16/sh) vs $5.0M ($0.26/sh) prior year; revenue $0.9M down from $1.4M
ProPhase Labs engages ThinkEquity for $6M private placement; crypto treasury strategy
Exclusive strategic advisory and placement agent agreement for proposed $6M private placement of securities on best efforts basis.
ProPhase Labs shareholders approve share increase to 1B and equity plans
Shareholders approved increase in authorized common shares from 50M to 1B at Sept 9 special meeting.
ProPhase Labs terminates $7.7M equity line with Keystone Capital Partners
Terminated Common Stock Purchase Agreement with Keystone Capital Partners effective August 28, 2025.
Definitive proxy filed Aug 15; SEC completed review with no further comments on Aug 18.
Q2 revenue $1.2M vs $1.5M YoY; net loss from continuing ops $4.5M ($0.11/share) vs $5.5M ($0.29/share).
Special Meeting of Shareholders on August 29, 2025 to vote on increasing authorized shares to 1 billion.
ProPhase Labs raises $2.75M via senior secured convertible notes with 20% OID and warrants
Notes have $3.75M face value after 20% OID; net proceeds ~$2.75M; mature July 22, 2026.
ProPhase Labs closes $3M senior secured convertible notes with warrants at $0.50
Notes have 20% original issue discount, secured by Company assets, not convertible for first 4 months.
Board unanimously authorized exploring reverse merger with a digital asset-focused operating company (crypto treasury management).
ProPhase Labs regains Nasdaq compliance after appointing new independent director
Appointed Carolina Abenante as independent director on June 20, 2025.
ProPhase Labs enters $1M bridge loan (20% OID) from CEO and investor; issues warrants
Each loan (CEO and investor) $500k principal, 20% OID ($625k face), 10% interest, 12-month maturity.
ProPhase Q1 net loss narrows to $4.7M, cuts costs, eyes Nebula sale, $50M recovery
Q1 net revenue $1.4M (down from $2.4M YoY); net loss $4.7M ($0.13/shr) vs $5.5M loss ($0.32/shr) last year.
On June 20, 2025, the Board of Directors (the “Board”) of ProPhase Labs, Inc. (the “Company”) appointed Carolina Abenante, Esq. to serve as an independent director to fill the existing vacancy on the Board.
Max materiality 0.90 · Median 0.60 · Most common event other_material